First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy.
Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, 1200 E Marshall St, Richmond, VA, 23298, USA.
Clin Transl Oncol. 2020 Sep;22(9):1603-1610. doi: 10.1007/s12094-020-02305-x. Epub 2020 Feb 11.
Since the role of resistin was evaluated only in patients with non-small cell lung cancer (NSCLC) not treated with immunotherapy, we aimed to evaluate levels of resistin during immunotherapy (nivolumab) and its prognostic role with regard to OS.
METHODS/PATIENTS: From a cohort of 78 patients with advanced NSCLC enrolled in a prospective study at Ospedale Policlinico San Martino in Genoa (Italy), 43 patients have been considered for this sub-analysis because of the availability of samples. Before and during nivolumab administration, clinical information and blood samples were collected and resistin, matrix metalloproteinase (MMP)-8, MMP-9, and myeloperoxidase were evaluated by enzyme-linked immunosorbent assay (ELISA).
Median age was 71 with a prevalence of males and former smokers. Median resistin levels presented a peak at cycle 2 and then dropped down until the last cycle. Resistin correlated with all neutrophil degranulation products at cycle 1 (except for MMP-9) and at cycle 2 as well as with white blood cells and neutrophils. By a ROC curve analysis, a resistin value at cycle 2 of 19 ng/mL was tested as the best cut-off point for OS. Kaplan-Meier analysis demonstrated that patients above the resistin cut-off experienced a reduced OS (median OS 242.5 vs. 470 days, p = 0.0073), as confirmed by Cox proportional hazards regression analysis.
Resistin levels > 19 ng/mL at the time of the second cycle of nivolumab treatment independently predict a reduced OS in patients with advanced NSCLC.
由于抵抗素的作用仅在未接受免疫治疗的非小细胞肺癌（NSCLC）患者中进行了评估，我们旨在评估免疫治疗（纳武利尤单抗）期间抵抗素的水平及其对 OS 的预后作用。
方法/患者：来自意大利热那亚圣马蒂诺医院一项前瞻性研究的 78 名晚期 NSCLC 患者队列中，有 43 名患者因有样本而被纳入此亚分析。在纳武利尤单抗给药之前和期间，收集临床信息和血液样本，并通过酶联免疫吸附试验（ELISA）评估抵抗素、基质金属蛋白酶（MMP）-8、MMP-9 和髓过氧化物酶。
中位年龄为 71 岁，男性和曾经吸烟者居多。中位抵抗素水平在第 2 周期时达到峰值，然后下降至最后一周期。在第 1 周期（除 MMP-9 外）和第 2 周期，抵抗素与所有嗜中性粒细胞脱颗粒产物以及白细胞和嗜中性粒细胞相关。通过 ROC 曲线分析，第 2 周期的抵抗素值 19ng/mL 被测试为 OS 的最佳截断点。Kaplan-Meier 分析表明，抵抗素值高于该截断点的患者 OS 降低（中位 OS 242.5 与 470 天，p=0.0073），这一结果在 Cox 比例风险回归分析中得到了证实。
在接受纳武利尤单抗治疗的第 2 周期时，抵抗素水平>19ng/mL 可独立预测晚期 NSCLC 患者的 OS 降低。
